New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
06:21 EDTDVADaVita could be weak on Medicare Advantage rates, says Piper Jaffray
Piper Jaffray believes shares of DaVita could be weak today following the release of Medicare's Advance Notice for 2015 Medicare Advantage rates, which it says was worse than expected. Piper notes Preliminary 2015 MA rates were down 7.8% versus expectations for a 6%-7% cut. The firm thinks final rates could improve and recommends buying shares of DaVita on any weakness. Piper maintains an Overweight rating on the stock with a $73 price target.
News For DVA From The Last 14 Days
Check below for free stories on DVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
10:02 EDTDVAOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:43 EDTDVADaVita downgraded to Market Perform from Outperform at Raymond James
Subscribe for More Information
July 18, 2014
16:05 EDTDVADaVita says CEO of HealthCare Partners subsidiary to step down
DaVita HealthCare Partners announced that HealthCare Partners, or HCP, president and CEO Dr. Craig Samitt is stepping down from HCP effective August 1. Kent Thiry, co-chairman and CEO of DaVita HealthCare Partners, will take over the role of CEO of HCP, working in tandem with the office of Chief Medical Officer.
July 17, 2014
07:00 EDTDVAFresenius Medical shares should be bought, says Bernstein
Bernstein notes that Fresenius' (FMS) stock has sharply underperformed versus its competitor, DaVita (DVA), since May 2012. But the firm predicts that Fresenius' core U.S. business should outperform that of DaVita going forward. Bernstein adds that it finds Fresenius' business units aside from its U.S. dialysis clinics more attractive than DaVita's businesses other than its U.S. dialysis clinics.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use